Pre-market 24 Mar 2026: Q0F.SI IHH Healthcare (SES) up 5.14% to S$3.07: catalysts

Q0F.SI stock jumped in the Singapore pre-market, trading at S$3.07 after a 5.14% intraday rise on 24 Mar 2026. We saw volume at 21,500 shares versus an average of 18,988, signalling genuine buying interest. The move lifts IHH Healthcare Berhad (Q0F.SI) toward its 52-week high, with traders eyeing the upcoming earnings due 28 May 2026. In this note we break down valuation, technicals, a proprietary Meyka AI forecast, and actionable scenarios for short-term traders and longer-term investors.

Q0F.SI stock: Pre-market price action and liquidity

IHH Healthcare Berhad (Q0F.SI) opened at S$2.83 and hit S$3.07 in pre-market trade on SES. Volume of 21,500 was above the average 18,988, giving the move conviction. The stock closed the prior session at S$2.92, so today’s change is S$0.15 or 5.14%. Short-term traders should note the day low was S$2.83 and the year low remains S$1.89.

Q0F.SI stock: Fundamentals and valuation

IHH shows EPS S$0.08 and a trailing PE of 38.38, above the healthcare peer average PE of 21.40 in Singapore. Price to book is 2.77 while book value per share is S$3.85. Market capitalisation is about S$27.13B. Operating cash flow per share is S$0.61, and dividend per share is S$0.10, indicating modest yield with a payout ratio near 28.0%.

Q0F.SI stock: Technicals and trend indicators

Momentum is positive: RSI stands at 61.09 and MACD histogram is 0.01, showing mild upward bias. The 50-day average is S$2.84 and the 200-day average is S$2.45, both below the current price. CCI at 131.84 signals near-term overbought conditions and ATR is S$0.10, implying moderate volatility. Traders should watch the Bollinger upper band near S$3.05 as a short-term resistance.

Q0F.SI stock: Meyka AI rates and analyst context

Meyka AI rates Q0F.SI with a score out of 100: 72.45, Grade B+ with a BUY suggestion. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. For comparison, an independent company rating dated 23 Mar 2026 shows a broad B (Neutral) view driven by mixed PE and debt metrics. Our grade highlights stronger cash flow and forecast upside in the model.

Q0F.SI stock: Price forecasts and target scenarios

Meyka AI’s forecast model projects a 1-year price of S$3.57 and a 3-year price of S$5.33. Relative to the current S$3.07, the 1-year model implies an upside of 16.29% and the 3-year scenario implies 73.65% upside. A conservative stress target is S$2.50, implying a downside of -18.57%. Forecasts are model-based projections and not guarantees.

Q0F.SI stock: Risks, catalysts and trading strategy

Key near-term catalyst is the earnings announcement on 28 May 2026 and regional patient volume trends across Malaysia and Singapore. Risks include higher-than-expected debt growth and stretched PE of 38.38. For traders we suggest watching earnings and a break of S$3.05 for momentum. Long-term investors should balance growth exposure with the company’s debt-to-equity of 0.58 and current ratio near 0.58.

Final Thoughts

Q0F.SI stock is the top pre-market gainer on 24 Mar 2026, trading at S$3.07 on SES with heavier-than-average volume and clear momentum. The shares show stretched valuation with a PE of 38.38, but cash flow metrics and a strong multi-year model tilt the risk-reward in favour of upside. Meyka AI’s forecast model projects S$3.57 in one year, an implied gain of 16.29% from today’s price; this projection sits alongside a conservative downside case to S$2.50. Investors should watch the 50-day average (S$2.84), upcoming earnings on 28 May 2026, and sector trends in Singapore healthcare. We use data-driven signals from Meyka AI’s platform to frame scenarios, not as investment advice. All forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.